Discovery of oral and inhaled PDE4 inhibitors

Expression, Purification, and Characterization of Human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D

Peng Wang, Joyce G. Myers, Ping Wu et al. · Biochemical and Biophysical Research Communications · 1997 · 127 citations

Life Sciences, Biochemistry, Molecular Biology +7

In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled Administration

Hildegard Kuss, Norbert Hoefgen, Sarah Johanssen et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 89 citations

Medicine, Medicinal Chemistry, Pharmacology +17

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma

Dave Singh, Frank Pétavy, Alex J. MacDonald et al. · Respiratory Research · 2010 · 88 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization

Cathy Tralau-Stewart, Richard A. Williamson, Anthony T. Nials et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 69 citations

Medicine, Medicinal Chemistry, Pharmacology +17

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD

Jørgen Vestbo, Lan‐Eng Tan, Gillian Atkinson et al. · European Respiratory Journal · 2009 · 67 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17